References
- Pormohammad A, Zarei M, Ghorbani S, Mohammadi M, Razizadeh MH, Turner DL, et al. Efficacy and safety of COVID-19 vaccines: a systematic review and meta-analysis of randomized clinical trials. Vaccines (Basel). 2021;9:467. doi: 10.3390/vaccines9050467.
- Forni G, Mantovani A. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021;28:626-39. doi: 10.1038/s41418-020-00720-9.
- World Health Organization.COVID-19 vaccine tracker and landscape. Geneva: World Health Organization; 2021.
- Cines DB, Bussel JB. SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia. N Engl J Med. 2021;384:2254-6. doi: 10.1056/NEJMe2106315.
- Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384:2092-101. doi: 10.1056/NEJMoa2104840.
- Schultz NH, Sorvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384:2124-30. https://doi.org/10.1056/NEJMoa2104882
- Pottegard A, Lund LC, Karlstad O, Dahl J, Andersen M, Hallas J, et al. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study. BMJ. 2021;373:n1114. doi: 10.1136/bmj.n1114.
- Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384:2202-11. doi: 10.1056/NEJMoa2105385.
- Simpson CR, Shi T, Vasileiou E, Katikireddi SV, Kerr S, Moore E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat Med. 2021;27:1290-7. doi: 10.1038/s41591-021-01408-4.
- Kharkar V, Vishwanath T, Mahajan S, Joshi R, Gole P. Asymmetrical cutaneous vasculitis following COVID-19 vaccination with unusual eosinophil preponderance. Clin Exp Dermatol. 2021;46:1596-7. doi: 10.1111/ced.14797.
- Cohen SR, Prussick L, Kahn JS, Gao DX, Radfar A, Rosmarin D. Leukocytoclastic vasculitis flare following the COVID-19 vaccine. Int J Dermatol. 2021;60:1032-3. doi: 10.1111/ijd.15623.
- Bostan E, Gulseren D, Gokoz O. New-onset leukocytoclastic vasculitis after COVID-19 vaccine. Int J Dermatol. 2021;60:1305-6. doi: 10.1111/ijd.15777.
- Watanabe T. Vasculitis following influenza vaccination: a review of the literature. Curr Rheumatol Rev. 2017;13:188-96. doi: 10.2174/1573397113666170517155443.
- Bonetto C, Trotta F, Felicetti P, Alarcon GS, Santuccio C, Bachtiar NS, et al. Vasculitis as an adverse event following immunization - systematic literature review. Vaccine. 2016;34:6641-51. doi: 10.1016/j.vaccine.2015.09.026.
- Guimaraes LE, Baker B, Perricone C, Shoenfeld Y. Vaccines, adjuvants and autoimmunity. Pharmacol Res. 2015;100:190-209. doi: 10.1016/j.phrs.2015.08.003.